1. Home
  2. CHNR vs BGLC Comparison

CHNR vs BGLC Comparison

Compare CHNR & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Natural Resources Inc.

CHNR

China Natural Resources Inc.

HOLD

Current Price

$3.70

Market Cap

5.1M

ML Signal

HOLD

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$3.97

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHNR
BGLC
Founded
N/A
2017
Country
China
Malaysia
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
10.1M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
CHNR
BGLC
Price
$3.70
$3.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.3K
58.7K
Earning Date
12-31-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.21
52 Week Low
$3.16
$2.01
52 Week High
$8.20
$15.60

Technical Indicators

Market Signals
Indicator
CHNR
BGLC
Relative Strength Index (RSI) 41.69 33.82
Support Level $3.36 $3.98
Resistance Level $4.22 $4.23
Average True Range (ATR) 0.18 0.14
MACD -0.02 0.01
Stochastic Oscillator 24.74 12.50

Price Performance

Historical Comparison
CHNR
BGLC

About CHNR China Natural Resources Inc.

China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: